RE:RE:Pancreatic surgeon Dr. Marty Makary appointed head of FDA
In May 2024 COSM recognized that " Durable Antitumor Immunity After Successful Primary Tumor Responses to IO Therapy is Conferred by CD8 Tex-stem Cells Residing Within Regional Lymphatics – Robert Saddawi-Konefka, MD, PhD "
Also in May 2024, the FDA approved of the tumor infiltrating lymphocyte (TIL) therapy lifileucel (LN-144) for the treatment of patients with advanced melanoma who progressed on or after anti–PD-1/PD-L1 therapy and targeted therapy.
ONCY's drug platform pelareorep is part of that promising referenced in the previous post. In particular, ONCY's AWARE-1 study showed that pelareorep treatment upregulated tumor PD-L1 expression, induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ TiL cells, and increased the CelTIL score, a measure of tumor cellularity and inflammation associated with favorable clinical outcomes.
Besides being able to overcome an immunosuppressive TME, pelareorp is a critical 'facilitator' in 'priming' the adaptive immune system in advance of PD-1 blockade, thus turning a 'cold' tumor into a 'hot' tumor that is more much conducive for PD-1 blockade, and a more effective I/O therapy than either agent alone. ---
https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=33526825